

Vyepti[™] (eptinezumab-jjmr) – New drug approval

- On February 21, 2020, <u>Lundbeck announced</u> the FDA approval of <u>Vyepti (eptinezumab-jjmr)</u>, for the preventive treatment of migraine in adults.
- Vyepti is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.
 - Vyepti is the first FDA-approved intravenous (IV) treatment for migraine prevention.
- The efficacy of Vyepti was established as a preventive treatment of episodic and chronic migraine in two randomized, placebo-controlled studies, both with 6-month double-blind periods: one study in patients with episodic migraine (study 1; N = 665) and one study in patients with chronic migraine (study 2; N = 1,072). In both studies, patients were randomized to receive placebo, Vyepti 100 mg, or Vyepti 300 mg. The primary endpoint was the change from baseline in mean monthly migraine days (MMD) over months 1 to 3.
 - In study 1, the change from baseline in mean MMDs over months 1 to 3 was -3.9, -4.3, and -3.2 for Vyepti 100 mg (p = 0.018 vs. placebo), Vyepti 300 mg (p < 0.001 vs. placebo), and placebo, respectively.</p>
 - In study 2, the change from baseline in mean MMDs over months 1 to 3 was -7.7, -8.2, and -5.6 for Vyepti 100 mg (p < 0.001 vs. placebo), Vyepti 300 mg (p < 0.001 vs. placebo), and placebo, respectively.
- A warning and precaution for Vyepti includes hypersensitivity reactions.
- The most common adverse reactions (≥ 2% and 2% or greater than placebo) with Vyepti use were nasopharyngitis and hypersensitivity.
- The recommended dose of Vyepti is 100 mg administered by IV infusion every 3 months. Some patients may benefit from a dosage of 300 mg administered by IV infusion every 3 months.
- Lundbeck plans to launch Vyepti in April 2020. Vyepti will be available as a 100 mg/mL solution in a single-dose vial.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.